Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Slides:

Advertisements

Similar presentations

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Advertisements

1. 2 The primary Objective of IDEAL LDL-C Simvastatin mg/d Atorvastatin 80 mg/d risk CHD In stable CHD patients IDEAL: The Incremental Decrease.

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Insights from clinical trials: The unassailable case for LDL-c.

Lipid Disorders and Management in Diabetes

Trial profile Fox K et al. Lancet 2008;372:

Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Cholesterol quintile (mg/dL)

How Aggressive do we get on Lipids? Christopher Cannon, M.D. Senior Investigator, TIMI Study Group Cardiovascular Division, Brigham and Women’s Hospital,

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Modern Management of Cholesterol in the High-Risk Patient.

10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.

1 Statin treatment is associated with improved prognosis in patients with AF-related stroke G. Ntaios, V. Papavasileiou, K.Makaritsis, A.Karagiannaki,

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

The overwhelming case for LDL-C lowering

BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.

Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.

The IDEAL Cholesterol Christopher Cannon, M.D. TIMI Study Group Brigham and Women’s Hospital Cannon CP. JAMA 2005;294:

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Beyond the Laboratory by Julian P.J. Halcox, and John E. Deanfield Circulation Volume 109(21 suppl 1):II-42-II-48 June 1, 2004 Copyright © American Heart.

Antonio Coca, MD, PhD, FRCP, FESC

NICE –CG 181 Continuum of CVD Risk and its treatment

Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial Michael Miller MD,

The SPRINT Research Group

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Copyright © 2011 American Medical Association. All rights reserved.

Clinical need for determination of vulnerable plaques

AIM HIGH Niacin plus Statin to prevent vascular events

CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study

First time a CETP inhibitor shows reduction of serious CV events

Copyright © 2012 American Medical Association. All rights reserved.

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Classification of total cholesterol levels

Oxford Niacin Trial.

Neil J. Stone et al. JACC 2014;63:

TNT Study: Baseline Characteristics of the Patients

Panelists. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

LRC-CPPT and MRFIT Content Points:

Potential mechanisms whereby statins may reduce the risk of stroke

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Baseline Characteristics of the Subjects*

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Delahoy PJ, et al. Clin Ther 2009;31:236-44

Characteristics of included studies

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

The ACCORD Study Group. NEJM 2010; Epub March 14

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Many post-MI patients are not receiving optimal therapy

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Number of ruptured plaques in addition to ruptured lesion in acute coronary syndrome (80% of patients with ≥1 ruptured plaque) A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Integrated approach to managing patients with acute coronary syndrome A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Kaplan-Meier estimates of the incidence of primary endpoint of death from any cause or a major cardiovascular event in PROVE IT-TIMI 22 A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

“Pleiotropic” effects of statins in acute coronary syndrome A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Cumulative incidence of recurrent myocardial infarction or death from coronary causes according to the achieved levels of both low density lipoprotein (LDL) cholesterol and C-reactive protein (CRP) in PROVE IT-TIMI 22 A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Relationship between the number of uncontrolled risk factors present and the median C-reactive protein (CRP) level for standard versus intensive statin therapy in PROVE IT-TIMI 22 A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Individual trials and pooled analysis showing a highly significant 16% reduction in the risk of coronary death or myocardial infarction (p<0.0001); CI - confidence interval, OR - odds ratio A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Benefit of intensive statin therapy versus moderate statin therapy in reducing the risk of hospitalization for heart failure in a meta-analysis of 27,546 patients A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Level of low density lipoprotein cholesterol achieved at 4 months and the long-term risk of death or major cardiovascular event A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Risk of major cardiovascular events according to quintile of achieved low density lipoprotein (LDL) cholesterol in Treating to New Targets study A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125

Recent coronary intravascular ultrasound trials (relationship between mean low density lipoprotein cholesterol level and progression rate of coronary atherosclerosis) A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125